Summary of Episode #348 – Women’s Sexual Health, Menopause, and Hormone Replacement Therapy (HRT) | Rachel Rubin, M.D.

Released on May 12, 2025, on "The Peter Attia Drive" podcast, hosted by Dr. Peter Attia, this episode features Dr. Rachel Rubin, a board-certified urologist and leading expert in women's sexual health. Their comprehensive discussion delves into the intricacies of menopause, hormone replacement therapy (HRT), and the often-overlooked aspects of women's sexual and hormonal health.

1. Introduction to Dr. Rachel Rubin and Her Expertise

Dr. Peter Attia opens the episode by introducing Dr. Rachel Rubin, highlighting her unique background as a urologist with specialized fellowship training in sexual health for both men and women. Dr. Rubin emphasizes her commitment to improving women's health beyond traditional urology, focusing on quality of life issues such as sexual function and hormonal health.

Notable Quote:

“Urologists are ultimately the quality of life doctors. We deal with urination problems and we deal with sexual medicine.”
[03:52] – Dr. Rachel Rubin

2. Understanding Menopause: A Physiological Overview

Menopause vs. Andropause: Dr. Rubin explains the fundamental endocrine differences between men and women as they age. While men experience a gradual decline in testosterone, women's hormone levels undergo a more abrupt and erratic change during perimenopause leading into menopause.

Key Points:

• Gas Tank Analogy: Menopause is likened to an empty gas tank, representing the sudden depletion of estrogen, progesterone, and testosterone.
• Hormonal Fluctuations: Perimenopause is characterized by volatile hormone levels, with estradiol (estrogen) fluctuating dramatically, akin to the stock market's ups and downs.

Notable Quote:

“Perimenopause is like driving 100 miles an hour on the highway and you go to an empty gas tank immediately. That is not good for a car.”
[07:43] – Dr. Rachel Rubin

3. The Risks of Menopause Without HRT

Dr. Rubin outlines the significant health risks associated with the decline of hormones post-menopause, including:

• Osteoporosis: Increased risk of fractures, with hip fractures having a mortality rate comparable to that of breast cancer.
• Cardiovascular Disease: Elevated risk post-menopause.
• Dementia and Alzheimer's: Higher incidence in women.
• Recurrent Urinary Tract Infections (UTIs): Due to hormonal changes affecting the urinary tract and microbiome.

Notable Quote:

“We have to ask the research questions and do this research because clinically, we see this all the time.”
[18:16] – Dr. Rachel Rubin

4. Historical Context of HRT and the Women's Health Initiative (WHI) Study

Evolution of HRT: Initially, HRT focused on replacing estrogen, which led to increased risks of endometrial cancer. The addition of progesterone mitigated this risk, establishing a safer HRT regimen.

Impact of the WHI Study: The WHI study, a large-scale randomized control trial, significantly altered the perception of HRT:

• Initial Findings: Indicated increased risks of breast cancer, blood clots, and cardiovascular disease, leading to a dramatic decline in HRT usage.
• Misinterpretation: Dr. Rubin argues that the study's results were misinterpreted, causing decades of fear-based medicine that deprived over 20 million women of HRT benefits.
• Subsequent Clarifications: Further analyses suggested that some of the WHI conclusions, particularly regarding breast cancer mortality, were flawed.

Notable Quote:

“This is the greatest injustice imposed by the modern medical system in our lifetime.”
[29:38] – Dr. Rachel Rubin

5. Current Challenges in HRT Prescription and Education

Lack of Medical Training: Less than 6% of internal medicine, OBGYN, or family practice doctors receive sufficient menopause education, leading to a shortage of knowledgeable prescribers.

Educational Gaps: Dr. Rubin underscores the absence of formal education on menopause management in medical curricula, resulting in widespread discomfort and reluctance among physicians to prescribe HRT.

Impact on Patient Care: Without proper training, many women do not receive the HRT they need, pushing them towards unregulated and often unsafe alternatives.

Notable Quote:

“We have a huge problem where you actually don't have any money to women's health.”
[31:13] – Dr. Rachel Rubin

6. Integrating Testosterone into Women's HRT

Role of Testosterone: Testosterone, though often overlooked, plays a crucial role in women's sexual health and overall well-being. Its decline begins in the 30s and continues through menopause, affecting libido, sexual function, and urinary health.

Therapeutic Use: Dr. Rubin advocates for the inclusion of testosterone in HRT regimens for symptom relief, particularly for low libido and improved sexual function.

Administration:

• Topical Application: Preferred method using testosterone gels at significantly lower doses than those prescribed for men to avoid androgenic side effects.
• Patience in Effects: Patients may begin to feel benefits within months, though some report improvements within weeks.

Notable Quote:

“When we add that testosterone piece, it's wild. All the patients come back and they say, 'I feel like me again.'”
[42:30] – Dr. Rachel Rubin

7. Delivery Methods for Estrogen and Progesterone

Estradiol Administration: Multiple forms are available, each with its own benefits and challenges:

• Oral Estradiol: Effective but associated with increased clotting factors due to first-pass liver metabolism. Preferred for patients without clotting risks.
• Transdermal Patches and Gels: Lower risk of blood clots and better for those with cardiovascular concerns. Patches offer customizable dosing but may not suit everyone.
• Vaginal Rings: Provide localized estrogen therapy, ideal for genitourinary symptoms without systemic effects.

Progesterone Administration: Essential for women with a uterus to prevent endometrial hyperplasia:

• Micronized Oral Progesterone: Typically starts at 100 mg daily or 200 mg cyclically.
• Vaginal Progesterone: Used for patients who experience adverse effects from oral forms.
• Progestin-Based IUDs: Provide localized progesterone without systemic side effects.

Notable Quote:

“We really have to change this on a big level, because I need the ICU doctors and the pulmonologists and the heart doctors and all the doctors to know that menopause affects their organs.”
[31:13] – Dr. Rachel Rubin

8. Addressing Lab Testing and Hormone Level Monitoring

Importance of Accurate Testing: Dr. Rubin emphasizes the necessity of using Liquid Chromatography-Mass Spectrometry (LC-MS) for accurate hormone level measurements, warning against the inaccuracies of ELISA-based assays.

Patient Guidance: Patients are encouraged to request LC-MS testing to ensure reliable results, which aid in tailoring HRT regimens effectively.

Notable Quote:

“We have seen that if you do not use the LC-MS assay, which is the very sensitive, the liquid chromatography assays, the results can be meaningless.”
[84:41] – Dr. Rachel Rubin

9. Managing Genitourinary Symptoms with Local Hormonal Therapy

Genitourinary Syndrome of Menopause (GSM): Previously termed "vulvovaginal atrophy," GSM includes symptoms like vaginal dryness, pain during intercourse, and increased UTIs.

Local Estrogen and DHEA:

• Vaginal Estrogen: Significantly reduces the risk of UTIs and alleviates GSM symptoms without systemic hormone effects.
• Vaginal DHEA (Intrarosa): Converts to both estrogen and testosterone locally, providing comprehensive symptom relief.

Economic Impact: Implementing widespread use of vaginal estrogen could save Medicare between $6 and $22 billion annually by reducing UTIs and associated healthcare costs.

Notable Quote:

“If everybody in Medicare eligibility used vaginal estrogen, we would save Medicare between 6 and $22 billion a year.”
[101:29] – Dr. Rachel Rubin

10. Overcoming Medical and Societal Barriers

Paternalistic Attitudes: Dr. Rubin criticizes the medical community's reluctance to embrace HRT, often rooted in outdated studies and fear-based approaches. She advocates for shared decision-making, where women are informed of the risks and benefits to make educated choices about their health.

Marketing and Misinformation: The negative legacy of the WHI study has been perpetuated by poor marketing and misinformation, leading to distrust and underutilization of HRT despite its proven benefits.

Call to Action:

• Education: Ongoing education for both patients and healthcare providers is crucial.
• Advocacy: Women should be empowered to seek knowledgeable practitioners and advocate for their health needs.
• Research: Continued research is necessary to refine HRT practices and address gaps in knowledge.

Notable Quote:

“Menopause has the worst PR campaign in the history of the universe.”
[93:16] – Dr. Rachel Rubin

11. Personalized HRT Regimens and Comprehensive Care

Tailored Treatments: Each woman's experience with menopause is unique, necessitating personalized HRT approaches. Dr. Rubin emphasizes understanding individual symptoms and adjusting hormone therapies accordingly.

Integration of Estrogen, Progesterone, and Testosterone: A balanced regimen often includes:

• Estradiol: For vasomotor symptoms, bone health, and overall well-being.
• Progesterone: To protect the endometrial lining in women with a uterus.
• Testosterone: To enhance libido and address sexual dysfunction.

Holistic Health Considerations: Dr. Rubin highlights that menopause affects multiple body systems, including musculoskeletal, cognitive, and emotional health, underscoring the need for a comprehensive treatment approach.

Notable Quote:

“Here, it is where the detectives work and get to the patients and get to the tools to solve the problem.”
[70:00] – Dr. Rachel Rubin

12. Conclusion and Future Directions

Dr. Rubin and Dr. Attia conclude by reiterating the critical need for informed and compassionate menopause care. They advocate for dismantling outdated fears surrounding HRT, enhancing medical education, and empowering women to take control of their hormonal health.

Final Thoughts:

• Advocacy for Change: Both speakers emphasize the urgency of transforming menopause care to prevent further health injustices.
• Hope for Progress: Encouraging signs of increased awareness and education offer optimism for future improvements in women's health.

Notable Quote:

“Menopause is killing men because it changes their marriages and it leads to divorce, which leads to death.”
[131:01] – Dr. Rachel Rubin

This episode serves as an essential resource for understanding the complexities of menopause and the pivotal role of HRT in enhancing women's quality of life. Dr. Rachel Rubin’s expertise provides a nuanced perspective, challenging long-held misconceptions and advocating for evidence-based, personalized care.